ArticleMolecular medicine reports2018
Identification of the tumor‑suppressive function of circular RNA FOXO3 in non‑small cell lung cancer through sponging miR‑155.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- A Meta-Analysis Approach to Gene Regulatory Network Inference Identifies Key Regulators of Cardiovascular Diseases.International journal of molecular sciences · 2024Pooled it
- Upregulation of Foxo3a protects neurons against hypoxia-ischaemia injury.Archives of medical science : AMS · 2026Article
- Therapeutic Potential of Circular RNAs as Targets for Cancer Treatment.Advanced pharmaceutical bulletin · 2025Review
- Role of circRNAs in regulating cell death in cancer: a comprehensive review.Cell biochemistry and biophysics · 2025Review
- Back to the Origin: Mechanisms of circRNA-Directed Regulation of Host Genes in Human Disease.Non-coding RNA · 2024Review
- Advanced approaches of the use of circRNAs as a replacement for cancer therapy.Non-coding RNA research · 2024Review
- CircRNA as an Achilles heel of cancer: characterization, biomarker and therapeutic modalities.Journal of translational medicine · 2024Review
- CircFOXO3 upregulation mediates the radioresistance of glioblastoma by affecting cellular metabolome.Frontiers in pharmacology · 2024Article
- Bioinformatics analysis and experimental verification of TIGD1 in non-small cell lung cancer.Frontiers in medicine · 2024Article
- Role of circ-FOXO3 and miR-23a in radiosensitivity of breast cancer.Breast cancer (Tokyo, Japan) · 2023Article
- The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target.Cancer cell international · 2023Review
- Understanding the roles and regulation patterns of circRNA on its host gene in tumorigenesis and tumor progression.Journal of experimental & clinical cancer research : CR · 2023Review
- The Tumorigenic Role of Circular RNA-MicroRNA Axis in Cancer.International journal of molecular sciences · 2023Review
- CircRNA has_circ_0017109 promotes lung tumor progression via activation of Wnt/β-catenin signaling due to modulating miR-671-5p/FZD4 axis.BMC pulmonary medicine · 2022Article
- The Role of miRNA-182 and FOXO3 Expression in Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Review
- Review
- Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.Journal of cellular and molecular medicine · 2022Article
- Circular RNA FOXO3 regulates endometrial carcinoma progression through the microRNA-29a-3p/HDAC4 axis.American journal of translational research · 2022Article
- The function and clinical implication of circular RNAs in lung cancer.Frontiers in oncology · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) are a class of endo-genous noncoding RNAs that have been demonstrated to be potential regulators in the development and progression of various types of human cancer. However, little is known about their roles in cancer initiation and progression, particular in non‑small cell lung cancer (NSCLC). In the present study, the expression level of circRNA‑forkhead box O3 class (FOXO3) in NSCLC specimens was determined and its functional role was investigated in NSCLC cells. By performing Taq‑man based RT‑qPCR, it was identified that circRNA‑FOXO3 was downregulated in NSCLC tissues and cell lines. Receiver operating curve analysis indicated that circRNA‑FOXO3 had a relatively higher diagnostic accuracy. The functional relevance was further examined by biological assays. circRNA‑FOXO3 significantly promoted the ability of cell proliferation, migration and invasion of NSCLC cells. The linear isomer of circRNA‑FOXO3, FOXO3 gene, was identified as a downstream target. RNA immunoprecipitation indicated that circRNA‑FOXO3 sequestering miR‑155, which further promoted linear FOXO3 expression. In addition, gain and loss functional assays indicated that circRNA‑FOXO3 served an anti‑oncogenic role through sequestering miR‑155 and enhancing FOXO3 expression. These results suggest that circRNA‑FOXO3 is a tumor‑suppressor in NSCLC and may serve as a promising therapeutic target. Therefore, restoration of circRNA‑FOXO3 expression could be a future approach to develop a novel treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.